Hemostatic and Fibrinolytic Abnormalities in Endocrine Diseases: A Narrative Review

Giovanni Targher; Isabella Pichiri; Giacomo Zoppini; Enzo Bonora; Michel Chonchol

doi:10.1055/s-0029-1242714

Seminars in Thrombosis and Hemostasis, Inhaltsverzeichnis

Semin Thromb Hemost 2009; 35(7): 605-612
DOI: 10.1055/s-0029-1242714

Hemostatic and Fibrinolytic Abnormalities in Endocrine Diseases: A Narrative Review

Giovanni Targher¹ , Isabella Pichiri¹ , Giacomo Zoppini¹ , Enzo Bonora¹ , Michel Chonchol²

¹Section of Endocrinology, Department of Biomedical and Surgical Sciences, University of Verona, Verona, Italy
²Division of Renal Diseases and Hypertension, University of Colorado Denver Health Sciences Center, Denver, Colorado

Abstract

ABSTRACT

This review summarizes current knowledge of the effects of polycystic ovary syndrome, Cushing's syndrome, thyrotoxicosis, hypothyroidism, primary hyperparathyroidism, acromegaly, hypopituitarism, and growth hormone deficiency on coagulation and fibrinolysis. Several abnormalities of the coagulation-fibrinolytic system have been described among patients affected by these endocrine disorders. Although further larger studies are needed to provide more definitive information, clinically overt hypothyroidism appears to be associated with a bleeding tendency, whereas all other endocrine diseases appear to be associated with a thrombotic tendency. The disorders of coagulation and fibrinolysis observed in these endocrine pathologies usually range from mild to moderate and, rarely, to potentially severe laboratory abnormalities (e.g., bleeding diathesis in overt hypothyroidism mainly due to an acquired von Willebrand's syndrome type 1), are reversible after pharmacologic treatment of the hormonal dysfunction, and are usually of limited consequence in clinical practice. Nevertheless, the prompt recognition of potentially severe disorders of blood coagulation is mandatory for the correct management of these patients.

KEYWORDS

Endocrine diseases - coagulation - fibrinolysis - hemostatic disorders - coagulation disorders

Volltext

Referenzen

REFERENCES

1 Kannel W B. Overview of hemostatic factors involved in atherosclerotic cardiovascular disease. Lipids. 2005; 40(12) 1215-1220
2 Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007; 357(24) 2482-2494
3 Fay W P, Garg N, Sunkar M. Vascular functions of the plasminogen activation system. Arterioscler Thromb Vasc Biol. 2007; 27(6) 1231-1237
4 Franchini M, Targher G, Montagnana M, Lippi G. The metabolic syndrome and the risk of arterial and venous thrombosis. Thromb Res. 2008; 122(6) 727-735
5 Mina A, Favaloro E J, Koutts J. Hemostatic dysfunction associated with endocrine disorders as a major risk factor and cause of human morbidity and mortality: a comprehensive meta-review. Semin Thromb Hemost. 2007; 33(8) 798-809
6 Targher G, Chonchol M, Miele L, Zoppini G, Pichiri I, Muggeo M. Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. Semin Thromb Hemost. 2009; 35(3) 277-287
7 Norman R J, Dewailly D, Legro R S, Hickey T E. Polycystic ovary syndrome. Lancet. 2007; 370(9588) 685-697
8 Meyer C, McGrath B P, Teede H J. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. J Clin Endocrinol Metab. 2005; 90(10) 5711-5716
9 Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf). 2000; 52(5) 595-600
10 Yildiz B O, Haznedaroğlu I C, Kirazli S, Bayraktar M. Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state. J Clin Endocrinol Metab. 2002; 87(8) 3871-3875
11 Kelly C J, Lyall H, Petrie J R et al.. A specific elevation in tissue plasminogen activator antigen in women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 2002; 87(7) 3287-3290
12 Atiomo W U, Bates S A, Condon J E, Shaw S, West J H, Prentice A G. The plasminogen activator system in women with polycystic ovary syndrome. Fertil Steril. 1998; 69(2) 236-241
13 Erdoğan M, Karadeniz M, Alper G E et al.. Thrombin-activatable fibrinolysis inhibitor and cardiovascular risk factors in polycystic ovary syndrome. Exp Clin Endocrinol Diabetes. 2008; 116(3) 143-147
14 Adali E, Yildizhan R, Kurdoglu M, Bugdayci G, Kolusari A, Sahin H G. Increased plasma thrombin-activatable fibrinolysis inhibitor levels in young obese women with polycystic ovary syndrome. Fertil Steril. 2009; , April 13 (Epub ahead of print)
15 Mak W, Dokras A. Polycystic ovarian syndrome and the risk of cardiovascular disease and thrombosis. Semin Thromb Hemost. 2009; 35 613-620
16 Orme S M, McNally R J, Cartwright R A, Belchetz P E. United Kingdom Acromegaly Study Group . Mortality and cancer incidence in acromegaly: a retrospective cohort study. J Clin Endocrinol Metab. 1998; 83(8) 2730-2734
17 Bates A S, Van't Hoff W, Jones J M, Clayton R N. An audit of outcome of treatment in acromegaly. Q J Med. 1993; 86(5) 293-299
18 Bogazzi F, Battolla L, Spinelli C et al.. Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study. J Clin Endocrinol Metab. 2007; 92(11) 4271-4277
19 Landin-Wilhelmsen K, Tengborn L, Wilhelmsen L, Bengtsson B A. Elevated fibrinogen levels decrease following treatment of acromegaly. Clin Endocrinol (Oxf). 1997; 46(1) 69-74
20 Erem C, Nuhoglu I, Kocak M et al.. Blood coagulation and fibrinolysis in patients with acromegaly: increased plasminogen activator inhibitor-1 (PAI-1), decreased tissue factor pathway inhibitor (TFPI), and an inverse correlation between growth hormone and TFPI. Endocrine. 2008; 33(3) 270-276
21 Wildbrett J, Hanefeld M, Fücker K et al.. Anomalies of lipoprotein pattern and fibrinolysis in acromegalic patients: relation to growth hormone levels and insulin-like growth factor I. Exp Clin Endocrinol Diabetes. 1997; 105(6) 331-335
22 Tomlinson J W, Holden N, Hills R K West Midlands Prospective Hypopituitary Study Group et al. Association between premature mortality and hypopituitarism. Lancet. 2001; 357(9254) 425-431
23 Elhadd T A, Abdu T A, Clayton R. Hypopituitarism and atherosclerosis. Ann Med. 2001; 33(7) 477-485
24 Johansson J O, Landin K, Tengborn L, Rosén T, Bengtsson B A. High fibrinogen and plasminogen activator inhibitor activity in growth hormone-deficient adults. Arterioscler Thromb. 1994; 14(3) 434-437
25 Johansson J O, Landin K, Johannsson G, Tengborn L, Bengtsson B A. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults. Thromb Haemost. 1996; 76(3) 422-428
26 Kvasnicka J, Marek J, Kvasnicka T et al.. Increase of adhesion molecules, fibrinogen, type-1 plasminogen activator inhibitor and orosomucoid in growth hormone (GH) deficient adults and their modulation by recombinant human GH replacement. Clin Endocrinol (Oxf). 2000; 52(5) 543-548
27 Elhadd T A, Abdu T A, Oxtoby J et al.. Biochemical and biophysical markers of endothelial dysfunction in adults with hypopituitarism and severe GH deficiency. J Clin Endocrinol Metab. 2001; 86(9) 4223-4232
28 Sesmilo G, Biller B M, Llevadot J et al.. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med. 2000; 133(2) 111-122
29 Devin J K, Blevins Jr L S, Verity D K et al.. Markedly impaired fibrinolytic balance contributes to cardiovascular risk in adults with growth hormone deficiency. J Clin Endocrinol Metab. 2007; 92(9) 3633-3639
30 Serri O, St-Jacques P, Sartippour M, Renier G. Alterations of monocyte function in patients with growth hormone (GH) deficiency: effect of substitutive GH therapy. J Clin Endocrinol Metab. 1999; 84(1) 58-63
31 Sartorio A, Cattaneo M, Bucciarelli P et al.. Alterations of haemostatic and fibrinolytic markers in adult patients with growth hormone deficiency and with acromegaly. Exp Clin Endocrinol Diabetes. 2000; 108(7) 486-492
32 Sesmilo G, Miller K K, Hayden D, Klibanski A. Inflammatory cardiovascular risk markers in women with hypopituitarism. J Clin Endocrinol Metab. 2001; 86(12) 5774-5781
33 Abdu T A, Elhadd T A, Buch H, Barton D, Neary R, Clayton R N. Recombinant GH replacement in hypopituitary adults improves endothelial cell function and reduces calculated absolute and relative coronary risk. Clin Endocrinol (Oxf). 2004; 61(3) 387-393
34 Völzke H, Schwahn C, Wallaschofski H, Dörr M. Review: The association of thyroid dysfunction with all-cause and circulatory mortality: is there a causal relationship?. J Clin Endocrinol Metab. 2007; 92(7) 2421-2429
35 Ochs N, Auer R, Bauer D C et al.. Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med. 2008; 148(11) 832-845
36 Squizzato A, Romualdi E, Büller H R, Gerdes V EA. Clinical review: thyroid dysfunction and effects on coagulation and fibrinolysis: a systematic review. J Clin Endocrinol Metab. 2007; 92(7) 2415-2420
37 Franchini M, Montagnana M, Manzato F, Vescovi P P. Thyroid dysfunction and hemostasis: an issue still unresolved. Semin Thromb Hemost. 2009; 35(3) 288-294
38 Franchini M, Lippi G, Manzato F, Vescovi P P. Thyroid-associated autoimmune coagulation disorders. J Thromb Thrombolysis. 2009; , March 10 (Epub ahead of print)
39 Homoncik M, Gessl A, Ferlitsch A, Jilma B, Vierhapper H. Altered platelet plug formation in hyperthyroidism and hypothyroidism. J Clin Endocrinol Metab. 2007; 92(8) 3006-3012
40 Burggraaf J, Lalezari S, Emeis J J et al.. Endothelial function in patients with hyperthyroidism before and after treatment with propranolol and thiamazol. Thyroid. 2001; 11(2) 153-160
41 Horne III M K, Singh K K, Rosenfeld K G et al.. Is thyroid hormone suppression therapy prothrombotic?. J Clin Endocrinol Metab. 2004; 89(9) 4469-4473
42 Demir T, Akinci B, Comlekci A et al.. Levothyroxine suppression treatment for benign thyroid nodules alters coagulation. Clin Endocrinol (Oxf). 2009; 71(3) 446-450
43 Erem C, Ersoz H O, Karti S S et al.. Blood coagulation and fibrinolysis in patients with hyperthyroidism. J Endocrinol Invest. 2002; 25(4) 345-350
44 Akinci B, Comlekci A, Yener S et al.. Thrombin activatable fibrinolysis inhibitor antigen levels are inversely correlated with plasminogen activator inhibitor-1 antigen levels in hyperthyroid patients. Endocr J. 2007; 54(4) 593-599
45 Erem C. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity. Clin Endocrinol (Oxf). 2006; 64(3) 323-329
46 Lippi G, Franchini M, Targher G et al.. Hyperthyroidism is associated with shortened APTT and increased fibrinogen values in a general population of unselected outpatients. J Thromb Thrombolysis. 2009; 28(3) 362-365
47 Müller B, Tsakiris D A, Roth C B, Guglielmetti M, Staub J J, Marbet G A. Haemostatic profile in hypothyroidism as potential risk factor for vascular or thrombotic disease. Eur J Clin Invest. 2001; 31(2) 131-137
48 Coban E, Yazicioglu G, Ozdogan M. Platelet activation in subjects with subclinical hypothyroidism. Med Sci Monit. 2007; 13 CR211-214
49 Gullu S, Sav H, Kamel N. Effects of levothyroxine treatment on biochemical and hemostasis parameters in patients with hypothyroidism. Eur J Endocrinol. 2005; 152(3) 355-361
50 Erikci A A, Karagoz B, Ozturk A et al.. The effect of subclinical hypothyroidism on platelet parameters. Hematology. 2009; 14(2) 115-117
51 Franchini M, Zugni C, Veneri D et al.. High prevalence of acquired von Willebrand's syndrome in patients with thyroid diseases undergoing thyroid surgery. Haematologica. 2004; 89(11) 1341-1346
52 Manfredi E, van Zaane B, Gerdes V EA, Brandjes D P, Squizzato A. Hypothyroidism and acquired von Willebrand's syndrome: a systematic review. Haemophilia. 2008; 14(3) 423-433
53 Chadarevian R, Bruckert E, Leenhardt L, Giral P, Ankri A, Turpin G. Components of the fibrinolytic system are differently altered in moderate and severe hypothyroidism. J Clin Endocrinol Metab. 2001; 86(2) 732-737
54 Michiels J J, Schroyens W, Berneman Z, van der Planken M. Acquired von Willebrand syndrome type 1 in hypothyroidism: reversal after treatment with thyroxine. Clin Appl Thromb Hemost. 2001; 7(2) 113-115
55 Chadarevian R, Jublanc C, Bruckert E et al.. Effect of levothyroxine replacement therapy on coagulation and fibrinolysis in severe hypothyroidism. J Endocrinol Invest. 2005; 28(5) 398-404
56 Erem C. Coagulation and fibrinolysis in thyroid dysfunction. Endocrine. 2009; 36(1) 110-118
57 Lundgren E, Lind L, Palmér M, Jakobsson S, Ljunghall S, Rastad J. Increased cardiovascular mortality and normalized serum calcium in patients with mild hypercalcemia followed up for 25 years. Surgery. 2001; 130(6) 978-985
58 Söreide J A, van Heerden J A, Grant C S, Yau Lo C, Schleck C, Ilstrup D M. Survival after surgical treatment for primary hyperparathyroidism. Surgery. 1997; 122(6) 1117-1123
59 Hedbäck G, Odén A. Persistent disease after surgery for primary hyperparathyroidism: the long-term outcome. Eur J Endocrinol. 2004; 150(1) 19-25
60 Lind L, Jacobsson S, Palmér M, Lithell H, Wengle B, Ljunghall S. Cardiovascular risk factors in primary hyperparathyroidism: a 15-year follow-up of operated and unoperated cases. J Intern Med. 1991; 230(1) 29-35
61 Erem C, Kocak M, Nuhoglu I, Yilmaz M, Ucuncu O. Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism. Eur J Endocrinol. 2009; 160(5) 863-868
62 Erem C, Kocak M, Hacihasanoglu A, Yilmaz M, Saglam F, Ersoz H O. Blood coagulation, fibrinolysis and lipid profile in patients with primary hyperparathyroidism: increased plasma factor VII and X activities and D-Dimer levels. Exp Clin Endocrinol Diabetes. 2008; 116(10) 619-624
63 Chertok-Shacham E, Ishay A, Lavi I, Luboshitzky R. Biomarkers of hypercoagulability and inflammation in primary hyperparathyroidism. Med Sci Monit. 2008; 14 CR628-632
64 Etxabe J, Vazquez J A. Morbidity and mortality in Cushing's disease: an epidemiological approach. Clin Endocrinol (Oxf). 1994; 40(4) 479-484
65 Mancini T, Kola B, Mantero F, Boscaro M, Arnaldi G. High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol (Oxf). 2004; 61(6) 768-777
66 Boscaro M, Sonino N, Scarda A et al.. Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome. J Clin Endocrinol Metab. 2002; 87(8) 3662-3666
67 Patrassi G M, Dal Bo Zanon R, Boscaro M, Martinelli S, Girolami A. Further studies on the hypercoagulable state of patients with Cushing's syndrome. Thromb Haemost. 1985; 54(2) 518-520
68 Patrassi G M, Sartori M T, Viero M L, Scarano L, Boscaro M, Girolami A. The fibrinolytic potential in patients with Cushing's disease: a clue to their hypercoagulable state. Blood Coagul Fibrinolysis. 1992; 3(6) 789-793
69 Fatti L M, Bottasso B, Invitti C, Coppola R, Cavagnini F, Mannucci P M. Markers of activation of coagulation and fibrinolysis in patients with Cushing's syndrome. J Endocrinol Invest. 2000; 23(3) 145-150
70 Terzolo M, Allasino B, Bosio S et al.. Hyperhomocysteinemia in patients with Cushing's syndrome. J Clin Endocrinol Metab. 2004; 89 3745-3751
71 Erem C, Nuhoglu I, Yilmaz M et al.. Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels. J Endocrinol Invest. 2009; 32(2) 169-174
72 Ambrosi B, Sartorio A, Pizzocaro A, Passini E, Bottasso B, Federici A. Evaluation of haemostatic and fibrinolytic markers in patients with Cushing's syndrome and in patients with adrenal incidentaloma. Exp Clin Endocrinol Diabetes. 2000; 108(4) 294-298
73 Van Zaane B, Nur E, Squizzato A et al.. Hypercoagulable state in Cushing's syndrome: a systematic review. J Clin Endocrinol Metab. 2009; 94(8) 2743-2750
74 Tauchmanovà L, Rossi R, Biondi B et al.. Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab. 2002; 87(11) 4872-4878
75 Arnaldi G, Angeli A, Atkinson A B et al.. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab. 2003; 88(12) 5593-5602

Giovanni TargherM.D.

Section of Endocrinology, Department of Biomedical and Surgical Sciences, University of Verona

Ospedale Civile Maggiore, Piazzale Stefani, 1, 37126 Verona, Italy

eMail: giovanni.targher@univr.it